PENNY FANNING: Open Payments
NPI 1912566365 · NORTH CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,509 in 103 payments from 36 companies in 2025. Trend: 2023 $2,317 · 2024 $2,756 · 2025 $2,509
Food & beverage: $2,509
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $217 |
| E.R. Squibb & Sons, L.L.C. | 10 | $185 |
| Merck Sharp & Dohme LLC | 8 | $182 |
| Kite Pharma, Inc. | 2 | $164 |
| Novocure Inc. | 3 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $124 |
| PFIZER INC. | 6 | $118 |
| AstraZeneca Pharmaceuticals LP | 5 | $117 |
| Celgene Corporation | 5 | $108 |
| Genentech USA, Inc. | 5 | $104 |
Products named: KEYTRUDA, Yescarta, Optune Lua (NovoTTF-200T), OPDIVO, SCEMBLIX, REBLOZYL, Venclexta, Nubeqa.
Industry payments across SC — which companies pay providers there.
